This is the authors' abstract. We don't add key points for this paper.
< 0.005). Overall, these studies demonstrate the ability of opaganib to induce ICD in tumor cells, which improves the antitumor activity of checkpoint antibodies.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Maines et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: